Core Insights - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for oncology and autoimmune diseases [3] - The company will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 [1] Company Overview - Nurix Therapeutics specializes in the discovery, development, and commercialization of targeted protein degradation medicines, aiming to enhance treatment options for cancer and inflammatory diseases [3] - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on immune cell activation [3] - Nurix is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline [3] - The partnered drug discovery pipeline includes a preclinical stage degrader of STAT6 in collaboration with Sanofi and a clinical stage degrader of IRAK4 in collaboration with Gilead, among other collaborations with major pharmaceutical companies [3] - Nurix utilizes a fully AI-integrated discovery engine and has significant expertise in ligase technology, positioning the company to lead in targeted protein degradation advancements [3]

Core Insights - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [3] - The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, featuring its president and CEO, Arthur T. Sands, M.D., Ph.D., and CFO, Hans van Houte [1] Company Overview - Nurix's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on enhancing immune cell activation [3] - The company is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline [3] - Nurix has partnered with Gilead Sciences, Sanofi, and Pfizer, retaining options for co-development, co-commercialization, and profit sharing in the U.S. for several drug candidates [3] - The company utilizes a fully AI-integrated discovery engine and has significant expertise in ligase, providing a competitive advantage in translating targeted protein degradation into clinical advancements [3]